 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or [0m
[34mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ENALAPRIL MALEATE increase or [0m
[32mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ENALAPRIL MALEATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ENALAPRIL MALEATE: pharmacodynamics: Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, [0m[1;31m2[0m[31m,[0m[1;31m569[0m[31m patients with all degrees of symptomatic heart failure and [0m
[31mejection fraction â‰¤[0m[1;31m35[0m[31m percent were randomized to placebo or enalapril and followed for up to [0m[1;31m55[0m[31m months [0m[1;31m([0m[31mSOLVD-Treatment[0m[1;31m)[0m[31m. Use of enalapril was associated with an [0m[1;31m11[0m[31m percent reduction in all-cause [0m
[31mmortality and a [0m[1;31m30[0m[31m percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina [0m[1;31m([0m[31m>[0m[1;31m2[0m[31m attacks/day[0m[1;31m)[0m[31m, hemodynamically [0m
[31msignificant valvular or outflow tract obstruction, renal failure [0m[1;31m([0m[31mcreatinine >[0m[1;31m2.5[0m[31m mg/dL[0m[1;31m)[0m[31m, cerebrovascular disease [0m[1;31m([0m[31me.g., significant carotid artery disease[0m[1;31m)[0m[31m, advanced pulmonary disease, malignancies, [0m
[31mactive myocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present. ENALAPRIL MALEATE: pharmacodynamics: A second [0m
[31mmulticenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction â‰¤[0m[1;31m35[0m[31m percent and no history [0m
[31mof symptomatic heart failure, were randomized to placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m117[0m[1;31m)[0m[31m or enalapril [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m111[0m[1;31m)[0m[31m and followed for up to [0m[1;31m5[0m[31m years. The majority of patients in the SOLVD-Prevention trial had a history of [0m
[31mischemic heart disease. A history of myocardial infarction was present in [0m[1;31m80[0m[31m percent of patients, current angina pectoris in [0m[1;31m34[0m[31m percent, and a history of hypertension in [0m[1;31m37[0m[31m percent. No statistically [0m
[31msignificant mortality effect was demonstrated in this population. Enalapril-treated subjects had [0m[1;31m32[0m[31m percent fewer first hospitalizations for heart failure, and [0m[1;31m32[0m[31m percent fewer total heart failure [0m
[31mhospitalizations. ENALAPRIL MALEATE: pharmacodynamics: Compared to placebo, [0m[1;31m32[0m[31m percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular[0m
[31mreasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group [0m[1;31m([0m[31mfor enalapril vs. placebo, respectively, [0m[1;31m1166[0m[31m vs. [0m[1;31m1201[0m[31m first [0m
[31mhospitalizations, [0m[1;31m2649[0m[31m vs. [0m[1;31m2840[0m[31m total hospitalizations[0m[1;31m)[0m[31m, although the study was not powered to look for such an effect. The SOLVD-Prevention trial was not designed to determine whether treatment of [0m
[31masymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of heart failure. [0m
[31mENALAPRIL MALEATE: pharmacodynamics: However, under the conditions of follow-up in the SOLVD-Prevention trial [0m[1;31m([0m[31mevery [0m[1;31m4[0m[31m months at the study clinic; personal physician as needed[0m[1;31m)[0m[31m, [0m[1;31m68[0m[31m percent of patients[0m
[31mon placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment. The SOLVD-Prevention trial was also not designed to show whether [0m
[31menalapril modified the progression of underlying heart disease. In another multicenter, placebo-controlled trial [0m[1;31m([0m[31mCONSENSUS[0m[1;31m)[0m[31m limited to patients with NYHA Class IV congestive heart failure and [0m
[31mradiographic evidence of cardiomegaly, use of enalapril was associated with improved survival. The results are shown in the following table. SURVIVAL [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Six Months One Year Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m127[0m[1;31m)[0m[31m [0m
[1;31m74[0m[31m [0m[1;31m64[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m126[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m48[0m[31m In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"35[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"33[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"33[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Enalapril Maleate<[0m[31m/[0m[31mcontent[0m[31m> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2314[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m> <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Incidence<[0m[31m/[0m[31mcontent[0m[31m> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Placebo<[0m[31m/[0m[31mcontent[0m[31m> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m([0m[31mn[0m[31m=[0m[1;31m230[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Incidence<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Body As A Whole<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31m ENALAPRIL MALEATE: adverse_reactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31mFatigue<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m3[0m[31m [0m[1;31m([0m[31m&lt;[0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m2.6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31mOrthostatic Effects<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.2[0m[31m [0m[1;31m([0m[31m&lt;[0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Asthenia<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.1[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0[0m[31m. ENALAPRIL MALEATE: [0m
[31madverse_reactions_table: [0m[1;31m9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Digestive<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.4[0m[31m [0m[1;31m([0m[31m&lt;[0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. ENALAPRIL MALEATE: [0m
[31madverse_reactions_table: [0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Nervous/Psychiatric<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m5.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m9.1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Dizziness<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m4.3[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m4[0m[31m. ENALAPRIL MALEATE: [0m
[31madverse_reactions_table: [0m[1;31m3[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Respiratory<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Cough<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m0.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Skin<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> Rash<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td[0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Enalapril maleate tablets, USP are indicated for the treatment of hypertension. Enalapril maleate tablets, USP are[0m
[31meffective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately [0m
[31madditive. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients [0m
[31menalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of [0m
[31msurvival trials[0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction [0m[1;31m([0m[31mejection fraction [0m
[31mâ‰¤[0m[1;31m35[0m[31m percent[0m[1;31m)[0m[31m, enalapril maleate tablets, USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart[0m
[31mFailure, Mortality Trials for details and limitations of survival trials[0m[1;31m)[0m[31m. In using enalapril maleate, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, [0m
[31mcaptopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not [0m
[31mhave a similar risk [0m[1;31m([0m[31msee WARNINGS , Neutropenia/Agranulocytosis [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: In considering use of enalapril maleate, it should be noted that in controlled clinical [0m
[31mtrials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been [0m
[31mreported to have a higher incidence of angioedema compared to non-blacks [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: clinical_pharmacology: Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of [0m
[31mheart failure as measured by the New York Heart Association [0m[1;31m([0m[31mNYHA[0m[1;31m)[0m[31m classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose and appeared to be [0m
[31mmaintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies [0m
[31mlasting from eight weeks to over one year. Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, [0m[1;31m2[0m[31m,[0m[1;31m569[0m[31m patients with all degrees of symptomatic heart failure and [0m
[31mejection fraction â‰¤[0m[1;31m35[0m[31m percent were randomized to placebo or enalapril and followed for up to [0m[1;31m55[0m[31m months [0m[1;31m([0m[31mSOLVD-Treatment[0m[1;31m)[0m[31m. Use of enalapril was associated with an [0m[1;31m11[0m[31m percent reduction in all-cause [0m
[31mmortality and a [0m[1;31m30[0m[31m percent reduction in hospitalization for heart failure. ENALAPRIL MALEATE: clinical_pharmacology: Diseases that excluded patients from enrollment in the study included severe stable[0m
[31mangina [0m[1;31m([0m[31m>[0m[1;31m2[0m[31m attacks/day[0m[1;31m)[0m[31m, hemodynamically significant valvular or outflow tract obstruction, renal failure [0m[1;31m([0m[31mcreatinine [0m[1;31m>[0m[1;31m2.5[0m[31m mg/dL[0m[1;31m)[0m[31m, cerebrovascular disease [0m[1;31m([0m[31me.g., significant carotid artery disease[0m[1;31m)[0m[31m, [0m
[31madvanced pulmonary disease, malignancies, active myocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present. A [0m
[31msecond multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction â‰¤[0m[1;31m35[0m[31m percent and no [0m
[31mhistory of symptomatic heart failure, were randomized to placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m117[0m[1;31m)[0m[31m or enalapril [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2[0m[31m,[0m[1;31m111[0m[1;31m)[0m[31m and followed for up to [0m[1;31m5[0m[31m years. ENALAPRIL MALEATE: clinical_pharmacology: The majority of patients in [0m
[31mthe SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in [0m[1;31m80[0m[31m percent of patients, current angina pectoris in [0m[1;31m34[0m[31m percent, and a history of [0m
[31mhypertension in [0m[1;31m37[0m[31m percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had [0m[1;31m32[0m[31m percent fewer first hospitalizations for heart failure,[0m
[31mand [0m[1;31m32[0m[31m percent fewer total heart failure hospitalizations. Compared to placebo, [0m[1;31m32[0m[31m percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for [0m
[31mcardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group [0m[1;31m([0m[31mfor enalapril vs. placebo, respectively, [0m[1;31m1166[0m[31m vs. [0m
[1;31m1201[0m[31m first hospitalizations, [0m[1;31m2649[0m[31m vs. [0m[1;31m2840[0m[31m total hospitalizations[0m[1;31m)[0m[31m, although the study was not powered to look for such an effect. ENALAPRIL MALEATE: clinical_pharmacology: The SOLVD-Prevention trial [0m
[31mwas not designed to determine whether treatment of asymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of [0m
[31menalapril at the earliest sign of heart failure. However, under the conditions of follow-up in the SOLVD-Prevention trial [0m[1;31m([0m[31mevery [0m[1;31m4[0m[31m months at the study clinic; personal physician as needed[0m[1;31m)[0m[31m, [0m[1;31m68[0m[31m percent[0m
[31mof patients on placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment. The SOLVD-Prevention trial was also not designed to [0m
[31mshow whether enalapril modified the progression of underlying heart disease. In another multicenter, placebo-controlled trial [0m[1;31m([0m[31mCONSENSUS[0m[1;31m)[0m[31m limited to patients with NYHA Class IV congestive heart [0m
[31mfailure and radiographic evidence of cardiomegaly, use of enalapril was associated with improved survival. The results are shown in the following table. ENALAPRIL MALEATE: clinical_pharmacology: [0m
[31mSURVIVAL [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Six Months One Year Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m127[0m[1;31m)[0m[31m [0m[1;31m74[0m[31m [0m[1;31m64[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m126[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m48[0m[31m In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both. [0m
[31mClinical Pharmacology in Pediatric Patients A multiple dose pharmacokinetic study was conducted in [0m[1;31m40[0m[31m hypertensive male and female pediatric patients aged [0m[1;31m2[0m[31m months to â‰¤[0m[1;31m16[0m[31m years following daily oral [0m
[31madministration of [0m[1;31m0.07[0m[31m to [0m[1;31m0.14[0m[31m mg/kg enalapril maleate. At steady state, the mean effective half-life for accumulation of enalaprilat was [0m[1;31m14[0m[31m hours, and the mean urinary recovery of total enalapril and[0m
[31menalaprilat in [0m[1;31m24[0m[31m hours was [0m[1;31m68[0m[31m percent of the administered dose. Conversion of enalapril to enalaprilat was in the range of [0m[1;31m63[0m[31m to [0m[1;31m76[0m[31m percent.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: In patients treated with enalapril maleate, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy [0m
[31mwas [0m[1;31m12[0m[31m weeks. Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2314[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m230[0m[1;31m)[0m[31m Incidence Body As A Whole Fatigue [0m[1;31m3[0m[31m [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m2.6[0m[31m Orthostatic Effects [0m[1;31m1.2[0m[31m [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m Asthenia [0m[1;31m1.1[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Digestive [0m
[31mDiarrhea [0m[1;31m1.4[0m[31m [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Nausea [0m[1;31m1.4[0m[31m [0m[1;31m([0m[1;31m0.2[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Nervous/Psychiatric Headache [0m[1;31m5.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m9.1[0m[31m Dizziness [0m[1;31m4.3[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m4.3[0m[31m Respiratory Cough [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. ENALAPRIL MALEATE: adverse_reactions: [0m[1;31m9[0m[31m Skin Rash [0m[1;31m1.4[0m[31m [0m
[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m0.4[0m[31m Heart Failure Adverse experiences occurring in greater than one percent of patients with heart failure treated with enalapril maleate are shown below. The incidences represent the [0m
[31mexperiences from both controlled and uncontrolled clinical trials [0m[1;31m([0m[31mmaximum duration of therapy was approximately one year[0m[1;31m)[0m[31m. In the placebo-treated patients, the incidences reported are from the [0m
[31mcontrolled trials [0m[1;31m([0m[31mmaximum duration of therapy is [0m[1;31m12[0m[31m weeks[0m[1;31m)[0m[31m. The percentage of patients with severe heart failure [0m[1;31m([0m[31mNYHA Class IV[0m[1;31m)[0m[31m was [0m[1;31m29[0m[31m percent and [0m[1;31m43[0m[31m percent for patients treated with enalapril [0m
[31mmaleate and placebo, respectively. Enalapril Maleate [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m673[0m[1;31m)[0m[31m Incidence [0m[1;31m([0m[31mdiscontinuation[0m[1;31m)[0m[31m Placebo [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m339[0m[1;31m)[0m[31m Incidence Body As A Whole Orthostatic Effects [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m Syncope [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Chest Pain [0m[1;31m2[0m[31m.[0m
[31mENALAPRIL MALEATE: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.1[0m[31m Fatigue [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Abdominal Pain [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.4[0m[1;31m)[0m[31m [0m[1;31m2.1[0m[31m Asthenia [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m Cardiovascular Hypotension [0m[1;31m6.7[0m[31m [0m[1;31m([0m[1;31m1.9[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Orthostatic Hypotension [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.3[0m[31m [0m
[31mAngina Pectoris [0m[1;31m1.5[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Myocardial Infarction [0m[1;31m1.2[0m[31m [0m[1;31m([0m[1;31m0.3[0m[1;31m)[0m[31m [0m[1;31m1.8[0m[31m Digestive Diarrhea [0m[1;31m2.1[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.2[0m[31m Nausea [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Vomiting [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Nervous/Psychiatric Dizziness [0m[1;31m7.9[0m[31m [0m[1;31m([0m[1;31m0.6[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m. ENALAPRIL [0m
[31mMALEATE: adverse_reactions: [0m[1;31m6[0m[31m Headache [0m[1;31m1.8[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Vertigo [0m[1;31m1.6[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m1.2[0m[31m Respiratory Cough [0m[1;31m2.2[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Bronchitis [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m0.9[0m[31m Dyspnea [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0.1[0m[1;31m)[0m[31m [0m[1;31m0.4[0m[31m Pneumonia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Skin Rash [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m [0m
[31mUrogenital Urinary Tract Infection [0m[1;31m1.3[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m [0m[1;31m2.4[0m[31m Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in [0m[1;31m0.5[0m[31m to [0m[1;31m1[0m[31m percent of patients with [0m
[31mhypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity. Body As A Whole Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid [0m
[31mand Possibly Related Reactions [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: adverse_reactions: Cardiovascular Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in[0m
[31mhigh risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m; pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation,[0m
[31mRaynaud's phenomenon. Digestive Ileus, pancreatitis, hepatic failure, hepatitis [0m[1;31m([0m[31mhepatocellular [0m[31m or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, melena, anorexia, dyspepsia, constipation, [0m
[31mglossitis, stomatitis, dry mouth. Hematologic Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal Muscle cramps. ENALAPRIL MALEATE: adverse_reactions: [0m
[31mNervous/Psychiatric Depression, confusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy [0m[1;31m([0m[31me.g., paresthesia, dysesthesia[0m[1;31m)[0m[31m, dream abnormality. Respiratory Bronchospasm, rhinorrhea, [0m
[31msore throat and hoarseness, asthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, [0m
[31mpemphigus, herpes zoster, erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity. Special Senses Blurred vision, taste alteration, anosmia, tinnitus, [0m
[31mconjunctivitis, dry eyes, tearing. ENALAPRIL MALEATE: adverse_reactions: Urogenital Renal failure, oliguria, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, flank pain, [0m
[31mgynecomastia, impotence. Miscellaneous A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, [0m
[31marthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Angioedema Angioedema has been reported [0m
[31min patients receiving enalapril maleate, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ENALAPRIL MALEATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ENALAPRIL MALEATE increase or decrease the risk[0m
[31mof gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI have sent a query to FDAHandler to [0m
[32mgather information on whether ENALAPRIL MALEATE increases or decreases the risk of gastrointestinal ulcer hospitalization. However, I have not yet received a response that would allow me to provide an[0m
[32minformed answer. Therefore, at this moment, I must state that I do not know the answer to your question. If the FDA label data does not specify the answer, then my final response will remain [0m
[32mDO-NOT-KNOW. I will provide an update once I receive the necessary information from FDAHandler.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I sent a query to FDAHandler to ask about the risk of gastrointestinal ulcer hospitalization associated with ENALAPRIL MALEATE."[0m[32m,[0m
[32m      [0m[32m"I have not received information from FDAHandler that would allow me to provide an informed answer."[0m[32m,[0m
[32m      [0m[32m"Without specific information from the FDA label data, I cannot provide a reliable answer."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I sent a query to FDAHandler to ask about the risk of gastrointestinal ulcer hospitalization associated with ENALAPRIL MALEATE."[0m[34m,[0m
[34m      [0m[34m"I have not received information from FDAHandler that would allow me to provide an informed answer."[0m[34m,[0m
[34m      [0m[34m"Without specific information from the FDA label data, I cannot provide a reliable answer."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ENALAPRIL MALEATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I sent a query to FDAHandler to ask about the risk of gastrointestinal ulcer hospitalization associated with ENALAPRIL MALEATE.[0m
[1;31m2[0m[31m. I have not received information from FDAHandler that would allow me to provide an informed answer.[0m
[1;31m3[0m[31m. Without specific information from the FDA label data, I cannot provide a reliable answer.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback [0m
[31mwas provided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question was whether ENALAPRIL MALEATE increases or decreases the risk of gastrointestinal ulcer hospitalization. I requested information from FDAHandler to answer this question. However, I have [0m
[32mnot received any data that would allow me to determine the effect of ENALAPRIL MALEATE on the risk of gastrointestinal ulcer hospitalization. Therefore, without specific information from the FDA label[0m
[32mdata, I cannot provide a reliable answer to this question.[0m
